The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Nuclear Medicine"
DOI: 10.1007/s12149-019-01376-3
Abstract: The primary aim of this study was to evaluate the volumetric therapy response via Ga-68 PSMA I&T PET/CT in patients treated with Lu-177 PSMA I&T therapy. The secondary purpose was to determine the impact of… read more here.
Keywords: response; therapy response; 177 psma; therapy ... See more keywords
Prognostic role of early prostate specific antigen changes after [177 Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of clinical investigation"
DOI: 10.1111/eci.14014
Abstract: BACKGROUND Approximately 10%-20% of prostate cancers progress to metastatic and castration-resistant forms (mCRPC). Radioligand (RLT) therapy with [177 Lu]Lu-prostate-specific membrane antigen (PSMA) is an emerging treatment for metastasized mCRPC and its efficacy is assessed not… read more here.
Keywords: 177 psma; prostate specific; prostate; therapy ... See more keywords
Visual deficit possibly caused by lutetium-177 PSMA treatment
Sign Up to like & getrecommendations! Published in 2018 at "BMJ Case Reports"
DOI: 10.1136/bcr-2018-225508
Abstract: This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient… read more here.
Keywords: deficit possibly; 177 psma; lutetium 177; psma ... See more keywords
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
Sign Up to like & getrecommendations! Published in 2021 at "Trials"
DOI: 10.1186/s13063-021-05733-4
Abstract: Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free survival (PFS) and… read more here.
Keywords: trial; study; hormone sensitive; 177 psma ... See more keywords